PMDD Explained: Symptoms, Causes, and What Actually Treats It

Your mood does not collapse every month because of weakness, stress, or how you handle life. For many women, there is a specific, measurable biological process driving it, and it has a clinical name.

Premenstrual dysphoric disorder, PMDD, is one of the most underdiagnosed conditions in women’s mental health. Not because clinicians lack tools to identify it, but because the women experiencing it are so often told it is just bad PMS, and they believe it.

What This Page Covers

• What PMDD actually is and how it differs from PMS
• The biology behind it, including what is happening in the brain
• How it is diagnosed correctly
• Every treatment option with evidence behind it
• What to do if symptoms are affecting your functioning
• How continuous medication monitoring matters for PMDD management

PMDD Is Not Severe PMS

The language around PMDD creates confusion. Most descriptions call it a “severe form of PMS,” which implies a spectrum where one is just worse than the other.

That framing is clinically inaccurate.

PMDD is a distinct DSM-5 diagnosis listed under depressive disorders, not in the same category as PMS. PMS describes a range of physical and mild emotional symptoms in the days before menstruation. PMDD is defined by its mood component: marked irritability, anger, depressed mood, anxiety, and emotional instability that cause clinically significant distress or functional impairment in the luteal phase.

The distinction matters because the treatment approach is different. PMS is managed primarily with lifestyle modifications. PMDD responds to FDA-approved pharmacological treatment.

PMDD affects three to eight percent of women worldwide, a prevalence comparable to generalized anxiety disorder or panic disorder. Women with PMDD who experience symptoms for one week per cycle accumulate approximately 8.6 cumulative years of symptoms over their reproductive lifetime, comparable to the symptom burden of recurrent major depressive disorder.

The Biology: What Is Actually Happening

PMDD is not caused by abnormally high or low hormone levels. Women with PMDD and women without it have similar levels of estrogen and progesterone across their cycles. The difference is in how their brains respond to normal hormonal fluctuations.

PMDD can be conceptualized as a disorder of suboptimal sensitivity to neuroactive steroid hormones. Its core symptoms are related to the increase of stress sensitivity due to the fluctuation of hormone levels in the luteal phase of the menstrual cycle.

Here is the specific mechanism. After ovulation, the corpus luteum produces progesterone, which the body converts to allopregnanolone (ALLO), a neurosteroid that acts as a positive modulator of GABA-A receptors in the brain. GABA is the primary inhibitory neurotransmitter, calming neural activity and regulating mood. In most women, allopregnanolone supports mood stability during this phase. In women with PMDD, the brain has altered sensitivity to these fluctuations.

A rapid decrease in allopregnanolone reduces the sensitivity of the GABA-A receptor, hindering the inhibitory effect of GABAergic neurons on pyramidal neurons, and increasing the excitability of pyramidal neurons, resulting in PMDD-like behavior.

In plain terms: the rise and fall of allopregnanolone across the luteal phase creates a neurochemical instability that a PMDD brain cannot smoothly adapt to. This is why symptoms emerge when hormones shift, not when they are at a fixed level.

This also explains why simply checking hormone levels cannot confirm PMDD. The problem is in the response, not in the amount.

What Symptoms Actually Look Like

DSM-5 requires five or more of the following symptoms in the week before menstruation, with at least one being a core mood symptom:

Core mood symptoms:

• Marked affective lability (sudden mood swings, feeling tearful)
• Marked irritability or anger, often with increased interpersonal conflicts
• Marked depressed mood, feelings of hopelessness, or self-deprecating thoughts
• Marked anxiety, tension, or feeling on edge

Additional symptoms:

• Decreased interest in usual activities
• Difficulty concentrating
• Fatigue or low energy
• Appetite changes, cravings
• Hypersomnia or insomnia
• Feeling overwhelmed or out of control
• Physical symptoms including breast tenderness, bloating, joint or muscle pain, or headaches

The critical diagnostic requirement is that these symptoms resolve within a few days of menstruation starting and are minimal or absent in the week after the period. If mood symptoms are present throughout the cycle, the diagnosis may be different.

PMDD has been linked to significantly elevated suicidal thinking and behavior. A 2021 analysis found that women with PMDD were at a nearly seven times higher risk of a suicide attempt than women without PMDD. This is a medical condition that warrants clinical attention, not a personal failing to be managed alone.

How PMDD Is Diagnosed

There is no blood test for PMDD. Diagnosis requires prospective symptom tracking, meaning symptoms are recorded as they occur across at least two menstrual cycles, not reported from memory.

The Daily Record of Severity of Problems (DRSP) is the most rigorously validated tool for this purpose. It captures daily ratings of mood, physical symptoms, and functional interference across the cycle. Retrospective recall tends to overestimate symptom severity and does not allow the clinician to confirm the luteal-only timing pattern required for diagnosis.

A clinician will also rule out conditions that can mimic or overlap with PMDD, including hypothyroidism, major depressive disorder with premenstrual exacerbation, perimenopause in older patients, and anxiety disorders.

Comorbidities are common. PMDD can share symptoms with other conditions, including major depressive disorder, ADHD, and thyroid disease. The key distinguishing feature is that PMDD symptoms are not persistent: they come and go with the menstrual cycle.

Treatment: What the Evidence Supports

SSRIs: First-Line, FDA-Approved, Fast-Acting

SSRIs are the most evidence-based pharmacological treatment for PMDD. Three SSRIs carry explicit FDA approval for PMDD: sertraline (Zoloft), fluoxetine (Prozac, Sarafem), and controlled-release paroxetine (Paxil CR).

A 2024 Cochrane systematic review of 34 randomized controlled trials involving 4,563 participants found that SSRIs probably reduce both overall and specific premenstrual symptoms, including physical, psychological, functional, and irritability subscales. Treatment was more effective when administered continuously than in the luteal phase only.

A unique feature of SSRI response in PMDD is its speed. In depression, SSRIs typically require four to eight weeks to produce benefit. In PMDD, response often emerges within one to two cycles, and for some patients within the first luteal phase of treatment. This rapid onset supports the theory that SSRIs are acting on the ALLO-GABA system rather than solely on serotonin reuptake.

Dosing options:

• Continuous daily dosing: Taken every day throughout the cycle. Produces the most consistent symptom reduction.
• Luteal-phase dosing: Taken only during the two weeks before menstruation, then stopped after menses start. Works for many patients and reduces total medication exposure. More practical for women who dislike taking medication every day.

The three SSRIs with FDA approval for PMDD are sertraline, fluoxetine, and controlled-release paroxetine. They can be used at much lower doses than those required for major depressive disorder. For example, controlled-release paroxetine for PMDD typically starts at 12.5 mg, compared to 20 to 40 mg for depression.

The most common adverse effects of SSRI treatment in PMDD are nausea, asthenia, and somnolence. These are typically mild and transient.

Hormonal Contraceptives

Drospirenone-containing oral contraceptives, specifically the 24/4 formulation (Yaz), are FDA-approved for PMDD treatment. Drospirenone has anti-mineralocorticoid and anti-androgenic properties that may reduce physical symptoms and stabilize mood. The 24-day active pill formulation reduces the hormone-free interval, minimizing the hormonal drop that triggers luteal phase symptoms.

Hormonal contraceptives work differently from SSRIs: rather than modifying the brain’s response to hormonal fluctuations, they reduce the magnitude of the fluctuations themselves through ovulation suppression. For women who also want contraception, this can be an effective first-line option.

Not all hormonal contraceptives improve PMDD. Some formulations, particularly those with progestins that have higher androgenic activity, may worsen symptoms in some patients. The choice of formulation matters.

Gonadotropin-Releasing Hormone (GnRH) Agonists

For severe or treatment-resistant PMDD, GnRH agonists such as leuprolide suppress ovarian function and eliminate the hormonal fluctuations that drive PMDD entirely. Because they create a temporary medical menopause, they are not intended for long-term use without add-back hormone therapy. They are typically reserved for patients who have not responded to SSRIs or hormonal contraceptives.

Lifestyle and Behavioral Approaches

Aerobic exercise has consistent evidence for reducing PMDD symptom severity. Regular exercise modulates serotonin and dopamine activity, reduces HPA axis reactivity, and improves sleep, all mechanisms relevant to PMDD.

Reducing alcohol intake is clinically meaningful. Alcohol worsens GABA-A receptor dysregulation and fragments sleep, both of which amplify PMDD symptoms in the luteal phase.

Cognitive behavioral therapy has evidence for the mood and behavioral components of PMDD, particularly for addressing the catastrophic thinking patterns and interpersonal conflict that can escalate during the luteal phase.

About SiggyMD

PMDD management requires more than a prescription. SSRIs in PMDD are adjusted based on how the patient responds cycle to cycle: whether luteal-phase dosing is sufficient, whether the dose needs to be increased, and whether side effects in the first two weeks resolve. These are adjustments that happen in real time, not at quarterly appointments.

SiggyMD provides clinically supervised medication management with daily check-ins and prescriber access between visits. If you have mood symptoms that track your menstrual cycle and are interfering with your work, relationships, or sense of self, the anonymous intake requires no account, no name, and no email to begin.

“PMDD is one of the most undertreated conditions I see precisely because women have been told for years that it is just PMS,” says Shannon Carres, Psych P.A., of the SiggyMD clinical team. “When they find out there is a clinical diagnosis, evidence-based treatment, and that their brain has been responding to a hormonal pattern they cannot control, that reframe changes everything.”

For more on how mood and hormones intersect across reproductive stages, read our guide on perimenopause and mental health.

Start your anonymous intake at SiggyMD to connect with a licensed prescriber who understands the hormonal dimension of mood and can evaluate whether PMDD or a related condition is part of your picture.

What Members Are Saying

SC

S.C., 34

PMDD

“I spent four years thinking I just didn’t handle stress well. Every month, the two weeks before my period, I became a different person. Rage over nothing. Crying at things that didn’t bother me the week before. When a prescriber finally tracked my symptoms with me and explained what PMDD actually is, I was relieved and furious at the same time. Relieved because it had a name. Furious because no one had mentioned it before. Low-dose sertraline in the luteal phase changed my month. I don’t lose two weeks anymore.”

MR

M.R., 29

PMDD with Anxiety

“I kept being told my anxiety was just hormonal and I should try yoga. When I pushed for an actual evaluation and tracked my symptoms properly, it was obvious what was happening. The pattern was there every cycle. Starting treatment made me realize how much energy I had been spending just surviving half of every month.”

Member stories reflect real experiences. Names and identifying details have been changed to protect privacy. Results vary. You can begin anonymous intake without an account, name, email, or payment.

The Bottom Line

PMDD is not a personality issue, a stress response, or something to endure. It is a DSM-5 depressive disorder driven by an abnormal brain response to normal hormonal fluctuations, with FDA-approved treatments that work.

Proper diagnosis requires prospective symptom tracking. Proper treatment requires a clinician who understands the biology, the dosing options, and the follow-up monitoring needed to adjust the plan as the patient responds.

If your mood changes follow your menstrual cycle, and those changes are affecting your life, that pattern deserves clinical attention.

Sources

1. National Institute of Mental Health. Premenstrual Dysphoric Disorder (PMDD). Accessed June 2026.

2. Jespersen C, Lauritsen MP, Frokjaer VG, Schroll JB. Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder. Cochrane Database of Systematic Reviews. 2024;8:CD001396.

3. Hantsoo L, Payne JL. Towards understanding the biology of premenstrual dysphoric disorder: from genes to GABA. Neuroscience and Biobehavioral Reviews. 2023;149:105168.

4. Modzelewski S, et al. Premenstrual syndrome: new insights into etiology and review of treatment methods. Frontiers in Psychiatry. 2024;15:1363875.

5. Luo X, Yu X, Yang T, Chen J. Role of allopregnanolone-mediated GABA-A receptor sensitivity in the pathogenesis of PMDD. Frontiers in Psychiatry. 2023;14:1140796.

6. Biggs WS, Demuth RH. Premenstrual syndrome and premenstrual dysphoric disorder. American Family Physician. 2011;84(8):918-924.

7. Mayo Clinic Press. Understanding PMDD and how symptoms change as you get older. Accessed June 2026.

8. Cleveland Clinic. Premenstrual Dysphoric Disorder (PMDD). Updated 2023.

9. Psychopharmacology Institute. Psychopharmacology for PMS and PMDD: Luteal phase dosing and choosing among SSRIs. Accessed June 2026.

10. Johns Hopkins Medicine. Premenstrual Dysphoric Disorder (PMDD). Accessed June 2026.